1. Switzerland Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
EvoNext Holdings S.A.

EvoNext Holdings S.A.

ELVAF
EvoNext Holdings S.A.US flagOther OTC
2.15
USD
- -
- -
15.50MMarket Cap
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
Revenue per Share
7.55
6.66
5.58
4.6
3.55
2.9
3.76
2.4
2.81
3.63
1.75
- -
- -
Basic EPS, GAAP
-13.65
-15.33
-18.93
-18.92
-20.21
-9.48
-7.02
-9.49
-11.72
-10.13
-19.5
0.14
-0.09
Free Cash Flow per Basic Share
-11.72
-15.18
-19.94
-18.41
-18.75
-11.84
-6.34
-9.2
-9.54
-4.94
-1.8
-0.34
-0.16
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
-24.49
-23.42
-29.94
-45.37
-26.74
-26.2
-31.52
-77.94
-78.45
-73.57
-77.23
-64.89
-64.98
Tangible Book Value per Share
17.3
27.91
42.42
22.51
49.91
17.95
12.53
6.74
5.25
3.17
1.03
0.91
0.82
Basic Weighted Avg Shares
1
1
2
2
2
3
3
3
4
4
5
7
7
Sales/Revenue/Turnover
9
9
9
9
7
9
12
8
10
16
9
- -
- -
Operating Margin (%)
-203.16
-265.21
-422.26
-480.09
-655.79
-344.09
-173.57
-330.27
-425.5
-259.93
-533.65
- -
- -
Depreciation Expense
3
4
7
7
5
5
8
8
9
8
5
- -
- -
Net Income, GAAP
-16
-21
-32
-36
-39
-29
-22
-30
-41
-43
-105
1
-1
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
-180.7
-230.03
-339.29
-411.2
-569.28
-327.05
-186.61
-396.12
-417.78
-279.07
-1,114.98
- -
- -
Working Capital
22
49
81
51
95
52
36
18
18
11
7
7
6
LT Debt
3
4
4
4
2
2
5
4
4
3
- -
- -
- -
Total Equity
83
175
203
173
221
194
173
145
132
106
6
7
6
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
-12.81
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
-0.24
- -
Return on Common Equity (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -

Capital Structure

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Working Capital

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-14.09%
-22.89%
-9.9%
Free Cash Flow
-19.29%
-40.64%
-53.14%
Net Income, GAAP
-6.94%
-15.53%
-162.53%
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
9
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
-19.5
2024
- -
- -
- -
- -
0.14
2025
- -
- -
- -
- -
-0.09

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
- -
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -

Company Description

APIChatGPT
CEO
Gerhard Lobmaier
Full Time Employees
49
Sector
Healthcare
Industry
Biotechnology
Address
Duggingerstrasse 23 Reinach BL Switzerland 4153
IPO Date
Jan 8, 2021
Website
evonextholdings.com
Similar Companies
Edesa Biotech, Inc. (EDSA)
Pharmiva AB (publ) (PHARM.ST)
Calidi Biotherapeutics, Inc. (CLDI)
uniQure N.V. (QURE)
Qrons Inc. (QRON)
Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. (603392.SS)
Business
Evolva Holding S.A. (Ticker: ELVAF) develops and commercializes sustainable ingredients using proprietary biotechnology processes for the flavor, fragrance, cosmetics, and life sciences industries. The company offers a portfolio of nature-identical ingredients, including Valencene for nootkatone production, nootkatone as a natural insect repellent and flavor compound, sclareol for fragrance applications, and specialty biotech-derived products such as resveratrol, vanillin alternatives, and saffron components; these are produced via fermentation technology that enables scalable, environmentally friendly manufacturing without reliance on traditional plant extraction or chemical synthesis. Evolva serves customers in food and beverage, personal care, consumer health, and pharmaceutical sectors, with operations spanning Europe, North America, and Asia. Founded in 2004 and headquartered in Reinach, Switzerland, the company focuses on high-value, biotech-enabled molecules targeting premium markets demanding natural and sustainable solutions. In recent developments, Evolva has pursued strategic expansions in its nootkatone platform through partnerships for commercial scaling and continued advancements in its fermentation technology suite to broaden ingredient offerings amid growing demand for biotech flavors and repellents.

Company News

APIChatGPT

  • seekingalpha.com

    Evolva Holding SA (ELVAF) Q2 2023 Earnings Call Transcript

  • seekingalpha.com

    Evolva Holding SA (ELVAF) Q4 2022 Earnings Call Transcript